<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist

Dr Marrit Putker, Organoid Research Scientist at CrownBioMeet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our new Utrecht site.

Welcome to CrownBio, would you like to introduce yourself and your background?

Thank you. My name is Marrit Putker and I am proud to be the first scientist at the new CrownBio facility in Utrecht in the Netherlands. I am a molecular cancer biologist by training with over 14 years of lab experience. Before starting at CrownBio, I was working as a Postdoctoral fellow in the lab of Hans Clevers, organoid pioneer and HUB founder. I worked with many kinds of organoid models in my research, including studying the day-night rhythm of tumor cells.

What will your new role and responsibilities at CrownBio entail?

As lead scientist it’s my task to set up a well-functioning lab and to recruit and train staff to grow the team. I’ll also be overseeing research projects and model development, both here in the Netherlands as well as in collaboration with our labs in America and China. At the Utrecht site, we’ll be combining R&D activities, such as developing novel organoid-based immuno-oncology assays, with client projects and I’ll be running these initiatives.

With my many years’ experience in the organoid field, I’ll also be helping to raise awareness in the industry on the advantages of using organoids as preclinical research models. I’m happy to share my knowledge on the opportunities and challenges of these models with both colleagues and clients.

You're one of the first staff at our new Netherlands site, how are you finding the challenge of setting up a new site?

It’s both an incredible opportunity and a challenge to setup a new lab from scratch! Being local to Utrecht is a great advantage as I know my way around and know who to speak to; luckily everyone is very happy to help. Also, being backed up by the global environment of CrownBio gives me great support, and it’s great to see everyone being so excited about our new site being realized.

You'll be bringing a lot of expertise around HUB Organoids™. Can you explain a bit more about these models and their key features?

HUB Organoids are like mini-organs in a dish. They grow out from the adult stem cells present in (epithelial) tissues, and retain the characteristics of the specific tissue that the cells were taken from. Like in the body, the stem cells are able to proliferate but also to differentiate into functional cells. Similarly, when growing organoids from a cancerous tissue, tumor organoids grow out that reflect the characteristics of that particular tumor.

Since we are able to grow these mini-organs almost indefinitely in a very reproducible manner this gives us the opportunity to generate biobanks of hundreds or even thousands of tumors (and their healthy counterparts). These reflect the vast variety of tumors and clinical patients, allowing us to study their (drug response) behaviour in vitro, making tumor organoids an invaluable tool for preclinical cancer research.

Can you explain what sets HUB Organoids apart from other organoid technologies?

Organoids can be grown from adult stem cells (ASCs), resulting in the patented HUB organoids, or from induced pluripotent stem cells (iPSCs) that in turn are differentiated into the organ of interest. The latter technology is slightly more flexible regarding tissue availability. As cells are reprogrammed all the way back to pluripotency, it’s possible to also grow organoids from tissues for which no HUB protocols are available (for example, non-epithelial tissues such as the brain or blood cells). However, it also often results in less mature and less reproducible models compared to HUB Organoids, and, on average, it takes more time to establish this type of organoid.

When it comes to tumor organoids, HUB Organoids have so far been unmatched. Generating iPSCs from a (mutated) tumor cell to then differentiate them into tumor organoids is very complex, if not virtually impossible. Moreover, it brings a lot of uncertainties regarding their representativeness of tumor biology and therefore their predictive strength.

In contrast, HUB Organoid Technology allows the growth of organoids directly from tumor (stem) cells, which therefore exactly represent the specific tumor we are interested in. Indeed, HUB Organoids are proven to closely recapitulate in vivo tumor morphology and drug responses.

Are there other any organoid technologies available for oncology research and drug development?

As I discussed above, growing iPSCs from tumor cells is not only a detour, but also comes with uncertainties. Alternatively, one could generate ‘minimal’ tumors from healthy organoids, by introducing driver mutations using eg CRISPR-Cas9 methods. These artificial tumors can be generated from both ASC and iPSC-derived organoids and can be interesting when you’re interested in particular mutations in a healthy background.

Other than that, no other in vitro organoid technology is available that represents tumor biology, drug responses, and patient populations so closely as HUB Organoids.

What do you think is the future/will be the next big developments in organoid research?

Growing organoids is getting more and more efficient, and assays currently in development will allow smaller numbers of organoids to be required per experiment. Combining this with novel high-throughput assays, possibly imaging-based, and innovative bioinformatic analysis, will allow for bigger screens with more output and faster turnaround times.

Identifying and specifying indications for specific drugs (“clinical trials in a dish”) can be combined in high-throughput matrix screens with lead compound identification, compound efficiency testing or even combinatory drug screens. We will be able to streamline the drug development timeline and fine-tune which patient cohorts will respond to particular treatments and which not, improving the starting point for clinical trials.

Next to this, we will be able to assay more complex interactions between cancer cells and their environment. Co-cultures of organoids with immune cells, but also with mesenchyme or microbiome components, in combination with these novel drug screening methods, will allow for answering a plethora of questions that haven’t even been asked yet!


Related Posts